SCHEMBL392972

SCHEMBL392972

Cn1cc(C(=O)OCOC(=O)N(CC(=O)O)C(C)(C)C)c2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.50
LMNA P02545 2/20 0.44
POLB P06746 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
ALDH1A1 P00352 2/20 0.43
MITF O75030 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
HTT P42858 1/20 0.43
RASGRP1 O95267 1/20 0.41
PRKCA P17252 1/20 0.41
PRKCE Q02156 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
UTS2R Q9UKP6 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
ALOX15 P16050 1/20 0.40
NFKB1 P19838 1/20 0.40
PMP22 Q01453 1/20 0.40
HTR4 Q13639 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL395048 0.88 LMNA (0.45) NR4A2LMNAPOLBNPSR1ALDH1A1
SCHEMBL393653 0.80 ADRB2 (0.46) NR4A2POLBALDH1A1MAPTKMT2A
SCHEMBL393416 0.77 ADRB2 (0.44) POLBMAPTHTT
SCHEMBL393285 0.76 NPC1 (0.48) POLBNPSR1ALDH1A1MAPTKMT2A
SCHEMBL392885 0.76 SCN1A (0.49) LMNAALDH1A1KMT2AKDM4E
SCHEMBL392770 0.75 L3MBTL1 (0.38) LMNAL3MBTL1
SCHEMBL394164 0.75 KDM4E (0.43) LMNAPOLBALDH1A1MAPTKMT2A
SCHEMBL390294 0.73 SCN1A (0.52) LMNAPOLBALDH1A1MAPTKMT2A
SCHEMBL392988 0.73 KDM4E (0.46) ALDH1A1MAPTKMT2AL3MBTL1KDM4E
SCHEMBL390381 0.73 MAPK1 (0.41) LMNAALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919879-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES Wyeth a Corporation of the State of Delaware (US) 2008-05-14 EP claimed
WO-2007027599-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES WYETH (US) 2007-03-08 WO claimed
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines WYETH (US) 2007-03-01 US claimed
US-8101590-B2 9-aminocarbonylsubstituted derivatives of glycylcyclines WYETH LLC (US) 2012-01-24 US disclosed
EP-1919879-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES Wyeth a Corporation of the State of Delaware (US) 2008-05-14 EP disclosed
WO-2007027599-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES WYETH (US) 2007-03-08 WO disclosed
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines WYETH (US) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines Q6ZSR9, GMPS, RPS10 NR4A2 3247/4885LMNA 2954/4885POLB 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.